Phase 2 Refractory Cancer Clinical Trials
15 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–15 of 15 trials
Recruiting
Phase 1Phase 2
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Refractory CancerB-cell LymphomaB-cell Malignancy+1 more
BeOne Medicines80 enrolled50 locationsNCT06634589
Recruiting
Phase 2
Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer
Prostate CancerRefractory Cancer
Wake Forest University Health Sciences50 enrolled2 locationsNCT04337580
Recruiting
Phase 1Phase 2
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
CancerSolid Tumor, AdultRefractory Cancer+1 more
Immatics US, Inc.375 enrolled21 locationsNCT03686124
Recruiting
Phase 2
Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
Refractory CancerRelapsed CancerLarge Cell Lymphoma, Diffuse
Dipenkumar Modi32 enrolled4 locationsNCT05852717
Recruiting
Phase 2
Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas
Refractory CancerPrimary Central Nervous System LymphomaRelapsed Cancer+1 more
Baptist Health South Florida15 enrolled1 locationNCT05681195
Recruiting
Phase 1Phase 2
Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC
Head and Neck CancerRecurrentRelapse+1 more
UNC Lineberger Comprehensive Cancer Center33 enrolled1 locationNCT06096038
Recruiting
Phase 1Phase 2
Pembrolizumab, Ibrutinib and Rituximab in PCNSL
Refractory CancerPrimary Central Nervous System LymphomaRecurrent Cancer+1 more
Dana-Farber Cancer Institute37 enrolled4 locationsNCT04421560
Recruiting
Phase 1Phase 2
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer
Refractory CancerRecurrent CancerChildhood Cancer+2 more
Australian & New Zealand Children's Haematology/Oncology Group90 enrolled14 locationsNCT06208657
Recruiting
Phase 1Phase 2
Study of GV20-0251 in Participants With Solid Tumor Malignancies
Solid Tumor CancerAdult Refractory CancerEndometrial Carcinoma (EC)+2 more
GV20 Therapeutics350 enrolled3 locationsNCT07070518
Recruiting
Phase 1Phase 2
IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors
CancerSolid Tumor, AdultRefractory Cancer+1 more
Immatics Biotechnologies GmbH145 enrolled24 locationsNCT05958121
Recruiting
Phase 1Phase 2
A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer
Metastatic CancerSolid TumorUnresectable Solid Tumor+3 more
Spago Nanomedical AB90 enrolled2 locationsNCT06184035
Recruiting
Phase 1Phase 2
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Solid Tumor, AdultCutaneous MelanomaRefractory Cancer+3 more
GV20 Therapeutics365 enrolled13 locationsNCT05669430
Recruiting
Phase 2
Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma
Refractory CancerClassical Hodgkin LymphomaRelapsed Cancer
University Health Network, Toronto37 enrolled1 locationNCT04510636
Recruiting
Phase 2
Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations
Lung CancerMelanomaPancreas Cancer+4 more
N.N. Petrov National Medical Research Center of Oncology20 enrolled1 locationNCT06229340
Not Yet Recruiting
Phase 2
An Exploratory Randomised Controlled Open-Label Study of Methadone Rotation versus Other Opioid Rotation for the Treatment of Refractory Cancer Induced Bone Pain
Refractory Cancer Induced Bone Pain
Dr Merlina Sulistio50 enrolled2 locationsACTRN12621000141842